Advertisement
Singapore markets open in 5 hours 3 minutes
  • Straits Times Index

    3,135.76
    -6.09 (-0.19%)
     
  • S&P 500

    5,137.08
    +40.81 (+0.80%)
     
  • Dow

    39,087.38
    +90.98 (+0.23%)
     
  • Nasdaq

    16,274.94
    +183.04 (+1.14%)
     
  • Bitcoin USD

    62,721.07
    +592.78 (+0.95%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,682.50
    +52.48 (+0.69%)
     
  • Gold

    2,091.60
    +36.90 (+1.80%)
     
  • Crude Oil

    79.81
    +1.55 (+1.98%)
     
  • 10-Yr Bond

    4.1800
    -0.0720 (-1.69%)
     
  • Nikkei

    39,910.82
    +744.62 (+1.90%)
     
  • Hang Seng

    16,589.44
    +78.04 (+0.47%)
     
  • FTSE Bursa Malaysia

    1,538.02
    -13.42 (-0.86%)
     
  • Jakarta Composite Index

    7,311.91
    -7,316.11 (-50.01%)
     
  • PSE Index

    6,919.59
    -25.12 (-0.36%)
     

AbbVie Should Consider a Dividend Cut -- Here's Why

AbbVie Should Consider a Dividend Cut -- Here's Why

Since its split from Abbott Laboratories in 2013, AbbVie (NYSE: ABBV) has been the third best-performing stock in terms of total returns on capital (assuming the dividend was reinvested) on the esteemed list of Dividend Kings. AbbVie's top-shelf performance has been due to two main factors. First up, the company successfully expanded Humira's label at a breakneck pace over this period, transforming it into the world's first pharma product to exceed $20 billion a year in sales.